In the wake of the success of modern immunotherapy, oncolytic viruses (OVs) are currently
seen as a potential therapeutic option for patients with cancer who do not respond or fail to …

Over the last 60 years an eclectic collection of microbes has been tested in a variety of pre-
clinical models as anti-cancer agents. At the forefront of this research are a number of virus …

Tumor immunotherapy, especially immune checkpoint blockade (ICB), has revolutionized
the cancer field. However, the limited response of tumors to immunotherapy is a major …

The low therapeutic efficacy of current cancer immunotherapy is related to nonimmunogenic
and immunosuppressive tumor microenvironments (TMEs). To overcome these limitations …

The development of cancer neoantigen vaccines that prime the anti-tumor immune
responses has been hindered in part by challenges in delivery of neoantigens to the tumor …

Oncolytic virotherapy has emerged as a promising treatment for human cancers owing to an
ability to elicit curative effects via systemic administration. Tumor cells often create an …

Background Monoclonal antibodies (mAbs) targeting negative regulators, or checkpoint
molecules (eg PD1/PD-L1 & CTLA4), of anti-tumoural T cells have demonstrated clinical …

Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus
supporting the establishment of therapeutically relevant tumor-specific immune responses …

Influenza A virus (IAV) genome comprises eight negative-sense RNA segments, of which the
replication is well orchestrated and the delicate balance of multiple segments are …

Oncolytic herpes simplex viruses (oHSVs) showed efficacy in clinical trials and practice.
Most of them gain cancer-specificity from deletions/mutations in genes that counteract the …